SCHEMBL19631346

SCHEMBL19631346

COC(=O)/C=C/c1ccc(C(=O)Nc2ccc3ncccc3c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.69
RAB9A P51151 6/20 0.69
POLB P06746 2/20 0.66
PABPC1 P11940 1/20 0.63
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
CYP3A4 P08684 2/20 0.54
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
MAPT P10636 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ACHE P22303 1/20 0.52
TRPV1 Q8NER1 1/20 0.52
ALOX15 P16050 1/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MMP9 P14780 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21356144 0.87 PABPC1 (0.66) NPC1RAB9APOLBPABPC1CASP3
SCHEMBL29761200 0.87 PABPC1 (0.66) NPC1RAB9APOLBPABPC1CASP3
SCHEMBL19631486 0.87 PABPC1 (0.66) NPC1RAB9APOLBPABPC1CASP3
SCHEMBL19631472 0.86 KDM4E (0.67) NPC1RAB9AKMT2ASMN1; SMN2KDM4E
SCHEMBL16595912 0.84 KMT2A (0.69) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL29679067 0.84 KMT2A (0.69) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL5909540 0.83 NPC1 (0.67) NPC1RAB9APOLBPABPC1CASP3
SCHEMBL5909541 0.83 NPC1 (0.67) NPC1RAB9APOLBPABPC1CASP3
SCHEMBL5909447 0.83 NPC1 (0.67) NPC1RAB9APOLBPABPC1CASP3
SCHEMBL5909442 0.83 NPC1 (0.67) NPC1RAB9APOLBPABPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN UNIV TAIPEI MEDICAL (TW) 2025-11-13 US disclosed
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-30 US disclosed
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-11 US disclosed
EP-3458444-B1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF UNIV TAIPEI MEDICAL (TW) 2022-06-22 EP disclosed
WO-2021013163-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (CN) 2021-01-28 WO disclosed
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2019-09-19 US disclosed
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2019-09-19 US disclosed
WO-2017200966-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF DCB-USA LLC (US) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284141-A1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF HDAC1, HDAC11, HDAC7 NPC1 791/4885RAB9A 3537/4885POLB 571/4885
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC5 NPC1 1951/4885RAB9A 3556/4885POLB 1364/4885
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC2 NPC1 2030/4885RAB9A 3557/4885POLB 1507/4885
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof HDAC1, HDAC11, HDAC7 NPC1 791/4885RAB9A 3537/4885POLB 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.